ExonHit, RedPath Deal Hits Snag as Medicare May Drop Coverage of Test

RedPath has until July 9 to respond to a Medicare contractor why coverage for its PathFinderTG-Pancreatic test should continue, and ExonHit is currently evaluating the consequences of the decision.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.